Figure 2.
Figure 2. Association of Teff gene expression with PFS, mutation load, and IDO1. (A) The association between the Teff gene signature and PFS in all patients treated with chemoimmunotherapy. (B) The percent of FL patients with high and low Teff scores (median cut-point) among the 3 mutation load groups. (C) The association between the Teff gene signature and PFS among mutation load groups. (D) The association between IDO1 (stratified by median IDO1 expression) and PFS among all patients treated with chemoimmunotherapy. (E) The correlation of Teff expression with levels of IDO1. HRs, 95% CIs, and P values were calculated by using a Cox proportional hazards model, adjusted for age, FLIPI, sex, and response to induction therapy.

Association of Teffgene expression with PFS, mutation load, and IDO1. (A) The association between the Teff gene signature and PFS in all patients treated with chemoimmunotherapy. (B) The percent of FL patients with high and low Teff scores (median cut-point) among the 3 mutation load groups. (C) The association between the Teff gene signature and PFS among mutation load groups. (D) The association between IDO1 (stratified by median IDO1 expression) and PFS among all patients treated with chemoimmunotherapy. (E) The correlation of Teff expression with levels of IDO1. HRs, 95% CIs, and P values were calculated by using a Cox proportional hazards model, adjusted for age, FLIPI, sex, and response to induction therapy.

Close Modal

or Create an Account

Close Modal
Close Modal